Accessibility Menu
BridgeBio Pharma logo

BridgeBio Pharma

(NASDAQ) BBIO

Current Price$68.75
Market Cap$13.50B
Since IPO (2019)+150%
5 Year+15%
1 Year+63%
1 Month-1%

BridgeBio Pharma Financials at a Glance

Market Cap

$13.50B

Revenue (TTM)

$579.96M

Net Income (TTM)

-$725.93M

EPS (TTM)

-$3.75

P/E Ratio

-18.40

Dividend

$0.00

Beta (Volatility)

1.40 (Average)

Price

$68.75

Volume

2,455,144.599

Open

$68.57

Previous Close

$68.63

Daily Range

$68.03 - $69.90

52-Week Range

$41.80 - $84.94

Estimated Earnings Date

Aug 4, 2026

BBIO: Motley Fool Moneyball Superscore

68

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BridgeBio Pharma

Industry

Biotechnology

Employees

839

CEO

Neil Kumar, PhD

Headquarters

Palo Alto, CA 94301, US

BBIO Financials

Key Financial Metrics (TTM)

Gross Margin

93.78%

Operating Margin

-98.40%

Net Income Margin

-125.17%

Return on Equity

36.00%

Return on Capital

-87.26%

Return on Assets

-52.95%

Earnings Yield

-5.43%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.50B

Shares Outstanding

195.86M

Volume

2.46M

Avg. Volume

2.55M

Financials (TTM)

Gross Profit

$543.90M

Operating Income

-$570.67M

EBITDA

-$608.84M

Operating Cash Flow

-$443.95M

Capital Expenditure

-$10.17M

Free Cash Flow

-$454.12M

Cash & ST Invst.

$940.19M

Total Debt

$3.38B

BridgeBio Pharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$194.52M

+66.8%

Gross Profit

$184.09M

+61.5%

Gross Margin

94.64%

N/A

Market Cap

$13.50B

N/A

Market Cap/Employee

$18.62M

N/A

Employees

725

N/A

Net Income

-$164.04M

+2.0%

EBITDA

-$112.55M

+10.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$940.19M

+73.9%

Total Debt

$3.38B

+82.2%

Accounts Receivable

$205.23M

+78.0%

Inventory

$32.98M

+734.1%

Long Term Debt

$2.81B

+51.7%

Short Term Debt

$573.41M

+10908.1%

Return on Assets

-52.95%

N/A

Return on Invested Capital

-1.03%

N/A

Free Cash Flow

-$197.35M

+1.7%

Operating Cash Flow

-$197.28M

+1.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EXELExelixis, Inc.
$51.34-0.02%
IONSIonis Pharmaceuticals, Inc.
$75.99+0.13%
JAZZJazz Pharmaceuticals plc
$230.25+1.92%
ASNDAscendis Pharma A/S
$238.59+4.64%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$16.14+0.00%
SOFISoFi Technologies
$17.29+0.01%
NOKNokia
$13.70-0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$74.44-0.10%

Questions About BBIO

What is the current price of BridgeBio Pharma?

BridgeBio Pharma is trading at $68.63 per share.

What is the 52-week range for BridgeBio Pharma?

Over the past 52 weeks, BridgeBio Pharma has traded between $41.80 and $84.94.

How much debt does BridgeBio Pharma have?

As of the most recent reporting period, BridgeBio Pharma reported total debt of $3.38B.

How much cash does BridgeBio Pharma have on hand?

BridgeBio Pharma reported $880.44M in cash and cash equivalents in its most recent financial results.

What is BridgeBio Pharma’s dividend yield?

BridgeBio Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.